Jamie L Van Etten
Overview
Explore the profile of Jamie L Van Etten including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
217
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang R, Van Etten J, Dehm S
BMC Genomics
. 2018 Apr;
19(1):270.
PMID: 29673323
Background: Insertions and deletions (indels) are a major class of genomic variation associated with human disease. Indels are primarily detected from DNA sequencing (DNA-seq) data but their transcriptional consequences remain...
2.
Bohn J, Van Etten J, Schagat T, Bowman B, McEachin R, Freddolino P, et al.
Nucleic Acids Res
. 2017 Nov;
46(1):362-386.
PMID: 29165587
Human Pumilio proteins, PUM1 and PUM2, are sequence specific RNA-binding proteins that regulate protein expression. We used RNA-seq, rigorous statistical testing and an experimentally derived fold change cut-off to identify...
3.
Van Etten J, Nyquist M, Li Y, Yang R, Ho Y, Johnson R, et al.
Cancer Res
. 2017 Sep;
77(19):5228-5235.
PMID: 28928128
Prostate cancer is the second leading cause of male cancer deaths due to disease progression to castration-resistant prostate cancer (CRPC). Androgen receptor (AR) splice variants including AR-V7 function as constitutively...
4.
Kohli M, Ho Y, Hillman D, Van Etten J, Henzler C, Yang R, et al.
Clin Cancer Res
. 2017 May;
23(16):4704-4715.
PMID: 28473535
Androgen receptor (AR) variant AR-V7 is a ligand-independent transcription factor that promotes prostate cancer resistance to AR-targeted therapies. Accordingly, efforts are under way to develop strategies for monitoring and inhibiting...
5.
Van Etten J, Dehm S
Endocr Relat Cancer
. 2016 Mar;
23(4):R207-17.
PMID: 27000662
Metastatic disease is responsible for the majority of prostate cancer deaths. The standard treatment for metastatic disease is surgical or chemical castration in the form of androgen deprivation therapy. Despite...